Maravai LifeSciences 株価情報 (NASDAQ: MRVI)

最新ニュース Maravai LifeSciences (NASDAQ:MRVI) 株価情報

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Piper Sandler analyst John Barnidge maintains Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) with a Neutral and lowers the price target from $38 to $36.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Lincoln National, Lowers Price Target to $36

DA Davidson analyst Matt Summerville maintains Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) with a Buy and lowers the price target from $100 to $85.

DA Davidson Maintains Buy on Crane NXT, Lowers Price Target to $85

Benchmark analyst Christopher Kuhn maintains Hub Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBG#NASDAQ">HUBG</a>) with a Buy and lowers the price target from $40 to $33.13.

HUBG

Benchmark Maintains Buy on Hub Group, Lowers Price Target to $33.13

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an average annual return of 15.92%. Currently, Halozyme Therapeutics has a market capitalization of $8.38 billion. 
Buying $100 In HALO: If an investor had bought $100 of HALO stock 15 years ago, it would be worth $921.02 today based on a price of $68.02 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746801014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

HALO

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years

Piper Sandler analyst Patrick Moley maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and raises the price target from $180 to $190.

COIN

Piper Sandler Maintains Neutral on Coinbase Global, Raises Price Target to $190

Benchmark analyst Mark Palmer maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Buy and raises the price target from $145 to $202.

DAVE

Benchmark Maintains Buy on Dave, Raises Price Target to $202

Benchmark analyst Nathan Martin maintains Core Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>) with a Buy and lowers the price target from $112 to $105.

Benchmark Maintains Buy on Core Natural Resources, Lowers Price Target to $105

<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="1024" height="768" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094948/Bear-Roller-Coaster.jpg" alt="" class="wp-image-12688" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094948/Bear-Roller-Coaster.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094948/Bear-Roller-Coaster-300x225.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09094948/Bear-Roller-Coaster-768x576.jpg 768w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h1 class="wp-block-heading">Rethinking Bear Market Rally Strategy&nbsp;</h1>
In yesterday&#8217;s post (&#8220;<a href="https://www.zerohedge.com/news/2025-05-08/still-bear-market-rally">Is This Still A Bear Market Rally?</a>&#8220;), we mentioned why that question mattered:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">We&#8217;ve got a source of alpha that works well during market rallies: Portfolio Armor&#8217;s top ten names. Since December of 2022, our weekly&nbsp;<a href="https://portfolioarmor.com/performance-top-names">top ten names</a>&nbsp;have averaged returns of 17.03% over the next six months, versus 10.75% for the&nbsp;SPDR S&amp;P 500 Trust&nbsp;(SPY). If this is a new bull market, it makes sense to start buying those top names again now, or placing bullish options trades on them. But if this is a bear market rally, it makes sense to wait.&nbsp;
</blockquote>
What happened on Thursday prompted us to rethink that. Two of Portfolio Armor&#8217;s top ten names from earlier in the week, Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) and D-Wave Quantum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)&#8230;
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="777" height="637" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095031/PA-Top-Names.png" alt="" class="wp-image-12689" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095031/PA-Top-Names.png 777w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095031/PA-Top-Names-300x246.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095031/PA-Top-Names-768x630.png 768w" sizes="(max-width: 777px) 100vw, 777px" /></figure>
&#8230;Exploded higher on the day, up&nbsp;~42%&nbsp;and&nbsp;~51%, respectively. Both moves were tied to near-term catalysts:&nbsp;earnings reports.
Here's what their charts looked like:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="834" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095344/GRPN-834x1024.jpg" alt="" class="wp-image-12690" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095344/GRPN-834x1024.jpg 834w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095344/GRPN-244x300.jpg 244w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095344/GRPN-768x943.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095344/GRPN.jpg 977w" sizes="(max-width: 834px) 100vw, 834px" /></figure>
</blockquote>
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="769" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095410/QBTS-769x1024.jpg" alt="" class="wp-image-12691" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095410/QBTS-769x1024.jpg 769w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095410/QBTS-225x300.jpg 225w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095410/QBTS-768x1023.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095410/QBTS.jpg 901w" sizes="(max-width: 769px) 100vw, 769px" /></figure>
These weren't lottery ticket plays. These were data-driven selections by the Portfolio Armor system, combined with catalysts.
Which brings us to a tactical update.
<h2 class="wp-block-heading">From Avoidance to Precision</h2>
If we are in a bear market rally—and signs still point that way—then broad, passive exposure is a blunt instrument. What we need instead is&nbsp;precision exposure: to names flagged by the model&nbsp;and&nbsp;poised to move on identifiable catalysts.
So, the revised approach:
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">&#x1f50d;&nbsp;Buy call options on top-ranked names from the Portfolio Armor system that have near-term catalysts, like earnings.
</blockquote>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">&#x23f3;&nbsp;Time the entry in the days leading up to the catalyst, and select expirations&nbsp;a few weeks out&nbsp;to absorb IV crush and capture any momentum continuation.
</blockquote>
This is key:&nbsp;we're not chasing the move after earnings—we're positioning for it ahead of time, using the system's statistical edge to identify names likely to outperform, and catalysts as accelerants.&nbsp;
We had success with trading our top names during the bull market. It&#8217;s time to apply it to the bear market rally.&nbsp;
<h2 class="wp-block-heading">Managing Volatility and Risk</h2>
Implied volatility tends to rise into events and collapse immediately afterward—a phenomenon known as&nbsp;IV crush. That's what punishes short-term call buyers who target weekly expiries.
To reduce that damage, the answer isn't avoiding the event—it's&nbsp;buying a little time. Choosing expiries 2–3 weeks past the catalyst lets you:
<ol class="wp-block-list">
<li>Hold through the event without binary pressure, and</li>
<li>Potentially ride post-event continuation, if the name trends as it did with GRPN and QBTS.</li>
</ol>
This isn't about gaming volatility—it's about giving the trade room to work.
<h2 class="wp-block-heading">Why This Works—Even in a Bear Market Rally</h2>
Bear market rallies are notorious for their fragility. Breadth is thin. Participation is uneven. But that's exactly why this works: the moves that&nbsp;do&nbsp;happen tend to be&nbsp;violent, especially when sparked by strong catalysts.
GRPN and QBTS weren't just good picks—they were&nbsp;correctly timed&nbsp;good picks. The Portfolio Armor system surfaced them, but it was the earnings schedule that amplified the opportunity.
It's not enough to know what names have edge; you need to know when that edge is likely to express itself.
<h2 class="wp-block-heading">From Passive to Surgical</h2>
Thursday's action served as a reminder: even in a cautious market, there are trades worth taking. Not in bulk. Not indiscriminately. But selectively, where&nbsp;signal meets narrative.
This revised playbook doesn't abandon caution; it refines it.
We'll continue watching for top Portfolio Armor names with near-term events—earnings, guidance, product news. And we'll be using&nbsp;options—not stock—to target those asymmetric bursts, minimizing downside while preserving explosive upside.
It's not about ignoring the macro. It's about executing tactically within it.
If you want a heads up when we place our next top names trade, you can subscribe to our trading Substack/occasional email list below.&nbsp;
And if you want to try your hand at trading our top names yourself, you can access them updated daily on&nbsp;<a href="https://portfolioarmor.com/">our website</a>&nbsp;and our iPhone app. You can download our app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image alignleft size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095531/PA-JPEG-1-1024x683.jpeg" alt="" class="wp-image-12692" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095531/PA-JPEG-1-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095531/PA-JPEG-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095531/PA-JPEG-1-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095531/PA-JPEG-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095638/Widget-1.jpg" alt="" class="wp-image-12693" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095638/Widget-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/09095638/Widget-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Earnings

Equities

Options

Opinion

Signals

Markets

GRPN

QBTS

Why This Works, Even In A Bear Market Rally

Piper Sandler analyst Crispin Love maintains Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) with a Overweight and raises the price target from $11.5 to $12.

Piper Sandler Maintains Overweight on Abacus Global Management, Raises Price Target to $12

Tech investor and CEO of ARK Invest, Cathie Wood, on Friday re-emphasized her bullish calls on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). However, Wood shed some light on potential headwinds ahead for Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)<a href="https://www.benzinga.com/25/05/45274539/cathie-wood-strengthens-ai-chip-holdings-with-nvidia-and-amd-purchases-reduces-palantir-position-by-another-38-8-million"> and Alphabet, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>). 
PLTR: ARK Invest has been reducing its position in Palantir across its portfolio funds, selling nearly $80 million worth of shares this week alone. Palantir is now Ark&#8217;s fifth-largest holding, making up 6.62% of the portfolio with a total value of $324.4 million.
Read Next: <a href="https://www.benzinga.com/general/health-care/25/05/45305392/unitedhealth-investors-claim-company-hid-profit-impact-of-ceos-murder?utm_source=articleShare">UnitedHealth Investors Claim Company Hid Profit Impact Of CEO&#8217;s Murder</a>&nbsp;
In a Friday morning interview on CNBC's Squawk Box, Wood said Palantir's government business remains strong and its "commercial business is on fire." However, she warned that Europe could be a threat to the company's remarkable growth if the EU moves further into the AI space.&nbsp;
GOOG: The disruptive tech investor pointed to artificial intelligence as a force that will "disrupt the traditional world order" and predicted that everyone will have an AI-powered personal assistant in the future. Wood said that humans using a search engine to find information will become a thing of the past as the "assistants will do much of the walking for us."&nbsp;
Referencing an Apple executive's comments on AI replacing search engines earlier this week, Wood said that it comes as "no surprise" that large language models are already taking<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45288753/google-at-staggering-42-discount-to-sp-500-after-150-billion-value-dive"> market share</a> from Google.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a>
BTC: Wood reiterated ARK Invest's bitcoin thesis with a base case scenario of $750,000 and a bull case of bitcoin reaching $1.5 million by 2030.&nbsp;
Limited supply, emerging markets use case and institutions continuing to move into bitcoin will drive the price of bitcoin higher, she predicted.&nbsp;
"We still have miles to go," Wood said as bitcoin traded around $103,000 Friday morning after reclaiming the $100,000 level on Thursday.&nbsp;
TSLA: Wood has long been a Tesla bull and on Friday<a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction"> she again</a> doubled-down on her call for the Elon Musk-led company to reach $2600 per share within the next five years.&nbsp;
She added that the $2600 Tesla price target does not include revenue from humanoid robots which Wood pegged as a $26 trillion revenue opportunity.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a></li>
</ul>
Photo: ChrisStock82/Shutterstock

Large Cap

Movers

Tech

$BTC

GOOG

GOOGL

PLTR

TSLA

Cathie Wood Says AI Will 'Disrupt The Traditional World Order' And Replace Search Engines Like Google

WIIM

HROW

HROW stock has given up its prior loss. Harrow shares were trading lower after the company reported worse-than-expected Q1 financial results.

Benchmark analyst Reuben Garner maintains Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) with a Buy and lowers the price target from $210 to $185.

Benchmark Maintains Buy on Installed Building Prods, Lowers Price Target to $185

Piper Sandler analyst Peter Keith reiterates YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Overweight and lowers the price target from $38 to $36.

Reiteration

YETI

Piper Sandler Reiterates Overweight on YETI Holdings, Lowers Price Target to $36

Benchmark analyst Josh Sullivan maintains ESCO Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) with a Buy and raises the price target from $190 to $200.

Benchmark Maintains Buy on ESCO Technologies, Raises Price Target to $200

Piper Sandler analyst Peter Keith reiterates Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Overweight and lowers the price target from $45 to $44.

Piper Sandler Reiterates Overweight on Valvoline, Lowers Price Target to $44

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday.
Shares of Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance <a href="https://www.benzinga.com/quote/PODD/earnings">above estimates</a>.
Insulet reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of 80 cents per share. The company reported quarterly sales of $569.00 million which beat the analyst consensus estimate of $543.40 million.
Insulet shares jumped 16.7% to $300.10 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Gogo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) jumped 42.2% to $10.77 after the company reported better-than-expected first-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) gained 42.2% to $4.00 after the company posted quarterly earnings and raised its FY25 outlook.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) rose 26.7% to $10.96 after the company reported better-than-expected quarterly EPS results.</li>
<li>nLIGHT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) surged 25.8% to $10.85 after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 24.8% to $57.25. Natural Grocers partnered with Contented Hen to offer premium eggs at introductory prices.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) gained 24.7% to $74.72 after the company reported better-than-expected first-quarter financial results.</li>
<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) rose 21.9% to $113.61 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 20% to $254.95.</li>
<li>Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) gained 18.3% to $9.21 following upbeat quarterly earnings.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 16% to $42.51. Toast reported quarterly earnings of nine cents per share, which missed the Street estimate of 12 cents. Quarterly revenue came in at $1.34 billion, in line with the consensus estimate.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) gained 13.7% to $55.83 after the company reported better-than-expected fourth-quarter sales results and issued first-quarter guidance above estimates.</li>
<li>Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) shares jumped 13.5% to $25.50 as the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter.</li>
<li>AvePoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) gained 11.8% to $19.47 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) gained 11.2% to $30.99 after the company reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) climbed 10.8% to $391.51 after the company reported better-than-expected third-quarter financial results.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) rose 10.7% to $39.62 following upbeat quarterly earnings.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) gained 10.1% to $18.68.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) climbed 9.4% to $20.27.</li>
<li>Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) rose 8.7% to $135.16 after the company reported better-than-expected sales results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 7.1% to $305.13. As the electric vehicle manufacturer is finalizing plans to launch operations in the third-largest car market in the world, Prashanth Menon, the Country Head for India for Tesla, has reportedly resigned after nine years with the CEO Elon Musk-led company.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45316242/how-to-earn-500-a-month-from-nrg-energy-stock-ahead-of-q1-earnings">How To Earn $500 A Month From NRG Energy Stock Ahead Of Q1 Earnings</a></li>
</ul>

Intraday Update

AVPT

GOGO

LASR

MCHP

MNSO

NGVC

OUST

PINS

PODD

PONY

TMDX

TOST

YELP

Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday

Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and lowers the price target from $14 to $10.

NTLA

Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $10

Piper Sandler analyst Peter Keith reiterates Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) with a Overweight and raises the price target from $68 to $77.

Piper Sandler Reiterates Overweight on Somnigroup International, Raises Price Target to $77

Piper Sandler analyst Brian Mullan maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and lowers the price target from $27 to $20.

Piper Sandler Maintains Neutral on Sweetgreen, Lowers Price Target to $20

In a market that&#8217;s swinging between AI mania and recession fear, Invesco is intervening with a fresh set of <a href="https://www.benzinga.com/etfs">three active ETFs </a>that vow to do more than simply track the herd—they&#8217;re built to think a bit harder and hedge a bit wiser.
The three ETFs — Invesco QQQ Hedged Advantage ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQHG#NASDAQ">QQHG</a>), Invesco Comstock Contrarian Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CSTK#BATS">CSTK</a>) and Invesco Managed Futures Strategy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IMF#BATS">IMF</a>)—debuted on Wednesday. The ETFs provide a diversified arsenal fueled by the company&#8217;s extensive bench of active managers. The <a href="https://www.prnewswire.com/news-releases/invesco-to-advance-active-capabilities-with-three-new-active-etfs-302448384.html">funds </a>seek to benefit investors seeking growth, downside protection, and reduced correlation—all packaged within the tax and trading efficiency of an ETF structure.
Also Read: <a href="https://www.benzinga.com/25/05/45302268/trump-talks-tariffs-tech-stocks-talk-gains-qqq-leads-the-charge">Trump Talks Tariffs, Tech Stocks Gain As QQQ Leads The Charge</a>
What&#8217;s Inside The Toolbelt?
QQHG: A strategic spin on a crowd-pleaser. QQHG follows the Nasdaq 100 Index but takes it one step further by adding an options overlay that helps control downside risk—ideal for those who desire growth potential without the sensation of walking a tightrope without a net.
CSTK: That&#8217;s the value-oriented hawks&#8217; play. It invests for capital appreciation and income by focusing on pricing disconnections—those infrequent occasions when a company&#8217;s stock is selling significantly below its intrinsic value. It&#8217;s contrarian, traditional and driven by Invesco&#8217;s proven Comstock team.
IMF: Don&#8217;t confuse it with global monetary authorities, but this IMF applies a systematic, long/short methodology to futures trading. With exposure to asset classes and geographies, it seeks to deliver long-term returns with low correlation to traditional markets. Consider it a volatility buffer with global reach.
The active ETF revolution is a pivot from the era of vanilla indexing to one that&#8217;s more subtle and more strategy-driven. Invesco is embracing that change by coupling rules-based investing with experienced human intuition—smart beta with acuter instincts.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45299690/oil-etfs-heat-up-as-opec-pump-up-us-uk-trade-deal-china-talks-fuel-rally">Oil ETFs Heat Up As OPEC+ Pump-Up, US-UK Trade Deal, China Talks Fuel Rally</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

Invesco Managed Futures Strategy ETF Invesco Comstock Contrarian Equity ETF

CSTK

QQHG

Smart, Hedged And Contrarian: Invesco's New ETFs Tackle Growth, Risk, Value Gaps

Press Releases

Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI

Legal

Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI

The Gross Law Firm Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRVI

MRVI Shareholders Have Opportunity to Lead the Maravai LifeSciences Holdings, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MRVI

Penny Stocks

Small Cap

MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

MRVI DEADLINE TODAY: Maravai LifeSciences (MRVI) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI

Comments

Maravai LifeSciences

ニュース

最新ニュース Maravai LifeSciences (NASDAQ:MRVI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル